Canada Pension Plan Investment Board Makes New $395.32 Million Investment in Boston Scientific Corporation $BSX

Canada Pension Plan Investment Board acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the second quarter, Holdings Channel.com reports. The fund acquired 9,262,404 shares of the medical equipment provider’s stock, valued at approximately $395,319,000.

A number of other hedge funds have also recently made changes to their positions in BSX. Manatuck Hill Partners LLC bought a new stake in shares of Boston Scientific during the second quarter worth about $544,000. Osterweis Capital Management Inc. acquired a new position in Boston Scientific during the 2nd quarter valued at about $30,258,000. Parkman Healthcare Partners LLC acquired a new position in Boston Scientific during the 2nd quarter valued at about $7,703,000. Legal & General Group Plc bought a new stake in Boston Scientific during the 2nd quarter worth approximately $431,890,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Boston Scientific in the second quarter worth approximately $115,346,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Edward J. Ludwig acquired 5,000 shares of the stock in a transaction on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David C. Habiger bought 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $49.86 on Wednesday. The business’s fifty day simple moving average is $46.44 and its 200 day simple moving average is $57.14. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The firm has a market capitalization of $72.26 billion, a P/E ratio of 20.19, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the company earned $0.75 EPS. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has approved a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BSX. Evercore set a $65.00 target price on Boston Scientific in a report on Monday, July 6th. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. Needham & Company LLC dropped their price objective on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Mizuho dropped their price target on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Finally, Oppenheimer cut their price target on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a report on Monday, July 27th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.